C-Bridge Capital, BioBAY Lead $38M Series A Round In Biopharmaceutical Service Firm CMAB BioPharm

Login to View

Chinese private equity firm C-Bridge Capital has teamed up with Suzhou bio-medical and medical high-tech park BioBAY in leading a US$38 million series A round in CMAB BioPharm, a contract development and manufacturing organization (CDMO) providing comprehensive pharmaceutical services to biopharma companies.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in